CRISPR Therapeutics's Options Frenzy: What You Need to Know - CRISPR Therapeutics (NASDAQ:CRSP)

Core Insights - Significant investors have adopted a bearish outlook on CRISPR Therapeutics, with 84% of trades being bearish compared to only 7% bullish [1] - The projected price targets for CRISPR Therapeutics range from $30.0 to $70.0 over the past three months [2] - Recent options trading activity indicates a focus on strike prices between $30.0 and $70.0, reflecting investor interest and liquidity [3] Options Activity - In the last 30 days, notable options activity includes a mix of puts and calls, with a total of 13 trades detected [1][4] - The total amount for put trades was $220,010, while call trades amounted to $579,566, indicating a higher investment in calls despite the bearish sentiment [1] - Specific trades include bearish sentiment on calls with strike prices of $60.00, $57.50, and $65.00, with total trade prices ranging from $57.6K to $166.6K [8] Market Position - CRISPR Therapeutics is a gene editing company utilizing Crispr/Cas9 technology to develop therapeutics for genetically defined diseases [9][10] - The company’s first approved drug, Casgevy, targets high unmet medical needs such as sickle-cell disease and transfusion-dependent beta-thalassemia [10] - Analysts have set an average price target of $66.75 for CRISPR Therapeutics, with individual targets ranging from $44 to $93 [11][12] Current Stock Performance - The current trading volume for CRISPR Therapeutics is 1,184,163, with the stock price at $54.37, reflecting a decrease of -0.38% [14] - Current RSI values suggest that the stock is neutral, indicating a balance between overbought and oversold conditions [14]